RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company

RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company is located in Glen Rock, United States on 126 Valley Road, Suite C. RespireRx Pharmaceuticals Inc.: A Biopharmaceutical Company is rated 3 out of 5 in the category biotechnology in United States. RespireRx Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain-mediated breathing and other disorders. Obstructive Sleep Apnea (OSA), the most common form of sleep apnea, affects 29.4 million Americans according to Frost & Sullivan, but only 5.9 million adults are diagnosed (23.5 million are undiagnosed).  OSA, besides causing next day sleepiness which is a major cause of motor vehicle and industrial accidents, and is co-morbid with cardiovascular disease, type 2 diabetes and other conditions.  Treatment options are limited and the most effective treatment, the CPAP device has a high non-compliance rate. RespireRx is developing dronabinol, a capsule that is already approved by the U.S. FDA  for other indications, for the treatment of OSA.  RespireRx believes that patients prescribed a capsule will be more compliant than patients prescribed a CPAP device. Two Phase II clinical trials are complete and we are preparing for Phase III. Dronabinol is D9-THC (delta 9-tetrahydrocannabinol), a synthetic version of a cannabinoid found naturally in marijuana.  It is considered a Schedule III drug by the U.S. government and prescriptions are monitored.  RespireRx is also developing a 2nd platform, our ampakine platform. Several Phase IIA clinical trials have been completed showing the prevention of opioid induced respiratory depression (opioid induced apnea) without offsetting the desired analgesic (pain killing) effects of the opioid. A human study has also shown evidence of efficacy in central sleep apnea (differs from obstructive sleep apnea). Animal studies in disordered breathing in models of spinal cord injury, Pompe Disease and premature birth were promising. There evidence that are potential opportunities in non-respiratory neurological conditions such as ADHD.